(603882)"GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD."Report for Q3 2026
Filed with SSE · Stock code 603882 · · 14 pages · Chinese
Summary by 6ix AI
The report indicates a slight decline in revenue compared to the same period last year, while net profit has significantly increased. The company emphasizes its focus on clinical needs and operational efficiency to enhance its competitive advantage in the medical diagnostics sector. The financial statements included in the report are unaudited, and the company assures the accuracy and completeness of the information provided.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Guangzhou Kingmed Diagnostics Group Co. Ltd. on 6ix
Earlier from Guangzhou Kingmed Diagnostics
- (603882)"GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD."Indicative Announcement on Change in Equity Interests of Shareholder Holding More Than 5% of the Shares Reaching 1% Threshold
- (603882)"GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD."Announcement on Termination of External Investment
- Announcement on Implementation Results of Share Repurchase and Share Changes
- Announcement on Results of the Initial Grant under the 2026 Restricted Share and Stock Option Incentive Plan
- Announcement on Change in Share Nature and Progress of the 2026 Restricted Share and Stock Option Incentive Plan
Follow Guangzhou Kingmed Diagnostics into a list and get an email when it puts out news.
Follow Guangzhou Kingmed Diagnostics